DR Horton : Helped by a technical support level
Entry price | Target | Stop-loss | Potential |
---|
$144.82 |
$164 |
$135 |
+13.24% |
---|
The medium term support area around 141.27 USD should allow DR Horton shares to re-establish an upward trend in the short term.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths● With a P/E ratio at 10.17 for the current year and 9.31 for next year, earnings multiples are highly attractive compared with competitors.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
● Over the past four months, analysts' average price target has been revised upwards significantly.
● Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
● The group usually releases upbeat results with huge surprise rates.
Weaknesses● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
● The average consensus view of analysts covering the stock has deteriorated over the past four months.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.